EDEN PRAIRIE, MN, Oct. 12, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – SANUWAVE Health, Inc. (OTCPK: SNWV), a leading provider of next-generation wound care products, is excited to announce that three abstracts highlighting the role of the company’s dermaPACE system in clinical cases were accepted to the Poster Presentation Hall at the upcoming 2022 Fall Symposium on Advanced Wound Care (SAWC) hosted by HMP Global. The conference is one of wound care’s most esteemed events and will take place at Caesars Palace, Las Vegas, Nevada from October 13-16, 2022.
The following clinical cases, which examine the use of dermaPACE in patients with chronic, complex, and challenging wounds, will be presented.
1.) The Use of Non-Invasive Extracorporeal Shockwave Therapy (ESWT) Pulsed Acoustic Cellular Expression (PACE) System In Complex Wounds Related To Erythromelalgia, A Rare Skin Condition.
Dr. Marcelo de Oliveira e Silva, HOSPITAL CAXIAS D´OR RIO DE JANEIRO general and plastic surgeon, UNIFESP Medical School Professor, Pontifical Catholic University (PUC) Carlos Chagas Medical Graduate Institute, coordinator, Quinta D'Or Hospital, specialist, evaluator, Brazilian Society of Plastic Surgery (SBCP), preceptor, Ivo Pitanguy Institute.
Dr. Paulo Roberto Castelleti Liborio Da Costa Brazilian Society of Plastic Surgery and Ivo Pitanguy Institute. Practices at Salgado Filho Municipal Hospital (Trauma Surgery,General Surgery) and Duque de Caxias D´Or Hospital as Plastic Surgeon
2.) Extracorporeal Shockwave Therapy (ESWT) PACE-Technology: Pilot Trial to Treat Mixed Etiologies Lower Leg Ulcer in a Mobile Setting; When All Else Failed
John David Thomas, MD, FAPWCA – Medical Director Solutions Medical Group, PLLC, Houston, TX. DIRECTOR OF WOUND CARE: Signature Home Health – Baytown, TX; The Heights of North Houston – Spring, TX; Park Manor, The Woodlands – The Woodlands, TX; IPR Healthcare Systems – Houston, TX; Crimson Heights – Humble, TX. SPEAKER: Kerecis Omega3 Fish Skin technology. FORMER-SPEAKER: Acelity / KCI San Antonio, TX; Tissue Regenix Woundcare Inc. San Antonio, TX
3.) Extracorporeal Shockwave Therapy (ESWT) Pace-Technology: A New Approach to an Old Nemesis-Pyoderma Gangrenosum
Dr Perry Mayer; Medical Director of The Mayer Institute (TMI), Center of Excellence Hamilton Ontario Canada
Representatives from SANUWAVE will be available at SAWC booth #619 in the exhibit hall for inquiries on their ENERGY FIRST product portfolio which includes both dermaPACE and UltraMIST. The company’s CEO, Kevin Richardson, and CRO, Jack Schlechtweg, will also be in attendance.
If you are attending the event and would like to schedule some time to meet with a team member, please email the company’s Marketing contact Sabrina Ruelle at Sabrina.Ruelle@Sanuwave.com so she can help facilitate a meet time.
Additional information regarding SANWUAVE’s product portfolio is available through their website at https://sanuwave.com/
SANUWAVE Health is focused on the research, development, and commercialization of its patented, non-invasive and biological response-activating medical systems for the repair and regeneration of skin, musculoskeletal tissue, and vascular structures.
SANUWAVE’s end-to-end wound care portfolio of regenerative medicine products and product candidates help restore the body’s normal healing processes. SANUWAVE applies and researches its patented energy transfer technologies in wound healing, orthopedic/spine, aesthetic/cosmetic, and cardiac/endovascular conditions.
This press release may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, such as statements relating to financial results and plans for future business development activities and are thus prospective. Forward-looking statements include all statements that are not statements of historical fact regarding intent, belief or current expectations of the Company, its directors or its officers. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond the Company’s ability to control. Actual results may differ materially from those projected in the forward-looking statements. Among the key risks, assumptions and factors that may affect operating results, performance and financial condition are risks associated with the regulatory approval and marketing of the Company’s product candidates and products, unproven pre-clinical and clinical development activities, regulatory oversight, the Company’s ability to manage its capital resource issues, competition, and the other factors discussed in detail in the Company’s periodic filings with the Securities and Exchange Commission. The Company undertakes no obligation to update any forward-looking statement.
INVESTOR RELATIONS CONTACT: